Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Medical Officer | January 29, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date January 29, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,817 |
Ending reported balance
After 2024-01-30 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-29 · Sale · Disposed 4,400 · Balance 46,400 F1: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Row 2 · 2024-01-29 · Sale · Disposed 2,758 · Balance 43,642 F2: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Row 3 · 2024-01-30 · Sale · Disposed 4,825 · Balance 38,817 F4: This transaction was executed in multiple trades at prices ranging from $18.53 to $22.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
F2: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.
F3: This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022.
F4: This transaction was executed in multiple trades at prices ranging from $18.53 to $22.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,825 | $21.55 | $103,979.72 |
DisclosureSEC source: 0000950170-24-009493 · ownership.xml · nonDerivative · entry 3 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,817 F4 · price: This transaction was executed in multiple trades at prices ranging from $18.53 to $22.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · acquired: This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,758 | $17.80 | $49,093.78 |
DisclosureSEC source: 0000950170-24-009493 · ownership.xml · nonDerivative · entry 2 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,642 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,400 | $17.80 | $78,322.20 |
DisclosureSEC source: 0000950170-24-009493 · ownership.xml · nonDerivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,400 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001843 · ownership.xml · derivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0001209191-23-011283 · doc4.xml · derivative · entry 2 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2033-02-15 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 23,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011283 · doc4.xml · nonDerivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,800 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/24, 1/26/25, 1/26/26 and 1/26/27. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,840 | $13.87 | $67,124.02 |
DisclosureSEC source: 0001209191-23-005744 · doc4.xml · nonDerivative · entry 2 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,675 F3 · price: This transaction was executed in multiple trades at prices ranging from $13.62 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · acquired: This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,385 | $13.89 | $60,908.97 |
DisclosureSEC source: 0001209191-23-005744 · doc4.xml · nonDerivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,515 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 261,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005367 · doc4.xml · derivative · entry 2 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2032-01-25 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 36,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005367 · doc4.xml · nonDerivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,900 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:27 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $32.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005908 · doc4.xml · derivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:25 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 200,000 | $0.00 Strike: $21.98 | $0.00 |
DisclosureSEC source: 0001209191-20-048218 · doc4.xml · derivative · entry 1 DALE STEPHEN · CIK 0001821709 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-08-23 F1 · derivative.exercise_date: 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.